Again in breast cancer, PEDF inhibits tumour cell-derived and endothelial cell-derived angiogenesis by downregulating the hypoxia-inducible factor alpha (HIF-1α) protein [64], separating it from failed clinical antiangiogenic drug entities such as sorafenib, endostatin and bevacizumab. Here, SERPINF1 is linked to breast carcinoma.